Zoetis Inc. (ZOE.DE)
EUR 162.78
(-1.01%)
EUR 162.78
(-1.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.34 Billion USD | 10.88% |
| 2022 | 2.11 Billion USD | 3.78% |
| 2021 | 2.03 Billion USD | 24.36% |
| 2020 | 1.63 Billion USD | 9.2% |
| 2019 | 1.5 Billion USD | 5.04% |
| 2018 | 1.42 Billion USD | 65.28% |
| 2017 | 864 Million USD | 5.24% |
| 2016 | 821 Million USD | 142.18% |
| 2015 | 339 Million USD | -41.85% |
| 2014 | 583 Million USD | 15.67% |
| 2013 | 504 Million USD | 15.6% |
| 2012 | 436 Million USD | 77.96% |
| 2011 | 245 Million USD | 122.73% |
| 2010 | 110 Million USD | 210.0% |
| 2009 | -100 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 599 Million USD | 14.1% |
| 2024 Q2 | 624 Million USD | 4.17% |
| 2023 FY | 2.34 Billion USD | 10.88% |
| 2023 Q3 | 596 Million USD | -11.18% |
| 2023 Q2 | 671 Million USD | 21.56% |
| 2023 Q4 | 525 Million USD | -11.91% |
| 2023 Q1 | 552 Million USD | 19.74% |
| 2022 Q3 | 529 Million USD | 0.0% |
| 2022 FY | 2.11 Billion USD | 3.78% |
| 2022 Q1 | 595 Million USD | 43.72% |
| 2022 Q2 | 529 Million USD | -11.09% |
| 2022 Q4 | 461 Million USD | -12.85% |
| 2021 Q1 | 559 Million USD | 55.71% |
| 2021 Q4 | 414 Million USD | -25.0% |
| 2021 FY | 2.03 Billion USD | 24.36% |
| 2021 Q3 | 552 Million USD | 7.81% |
| 2021 Q2 | 512 Million USD | -8.41% |
| 2020 Q2 | 377 Million USD | -10.87% |
| 2020 Q1 | 423 Million USD | 10.16% |
| 2020 Q3 | 479 Million USD | 27.06% |
| 2020 Q4 | 359 Million USD | -25.05% |
| 2020 FY | 1.63 Billion USD | 9.2% |
| 2019 Q2 | 371 Million USD | 18.91% |
| 2019 Q4 | 384 Million USD | -11.32% |
| 2019 Q3 | 433 Million USD | 16.71% |
| 2019 FY | 1.5 Billion USD | 5.04% |
| 2019 Q1 | 312 Million USD | -9.57% |
| 2018 Q1 | 352 Million USD | 334.57% |
| 2018 Q4 | 345 Million USD | -0.58% |
| 2018 FY | 1.42 Billion USD | 65.28% |
| 2018 Q3 | 347 Million USD | -9.64% |
| 2018 Q2 | 384 Million USD | 9.09% |
| 2017 FY | 864 Million USD | 5.24% |
| 2017 Q1 | 238 Million USD | 54.55% |
| 2017 Q4 | 81 Million USD | -72.82% |
| 2017 Q2 | 247 Million USD | 3.78% |
| 2017 Q3 | 298 Million USD | 20.65% |
| 2016 Q4 | 154 Million USD | -35.56% |
| 2016 FY | 821 Million USD | 142.18% |
| 2016 Q3 | 239 Million USD | 6.7% |
| 2016 Q2 | 224 Million USD | 9.8% |
| 2016 Q1 | 204 Million USD | 827.27% |
| 2015 FY | 339 Million USD | -41.85% |
| 2015 Q3 | 189 Million USD | 610.81% |
| 2015 Q2 | -37 Million USD | -122.42% |
| 2015 Q1 | 165 Million USD | 30.95% |
| 2015 Q4 | 22 Million USD | -88.36% |
| 2014 Q2 | 136 Million USD | -12.26% |
| 2014 FY | 583 Million USD | 15.67% |
| 2014 Q4 | 126 Million USD | -24.1% |
| 2014 Q3 | 166 Million USD | 22.06% |
| 2014 Q1 | 155 Million USD | 47.62% |
| 2013 Q1 | 140 Million USD | 1500.0% |
| 2013 Q2 | 128 Million USD | -8.57% |
| 2013 Q3 | 131 Million USD | 2.34% |
| 2013 Q4 | 105 Million USD | -19.85% |
| 2013 FY | 504 Million USD | 15.6% |
| 2012 FY | 436 Million USD | 77.96% |
| 2012 Q1 | 111 Million USD | 1133.33% |
| 2012 Q2 | 173 Million USD | 55.86% |
| 2012 Q4 | -10 Million USD | -106.17% |
| 2012 Q3 | 162 Million USD | -6.36% |
| 2011 Q1 | 76 Million USD | 0.0% |
| 2011 Q3 | 94 Million USD | 42.42% |
| 2011 Q2 | 66 Million USD | -13.16% |
| 2011 Q4 | 9 Million USD | -90.43% |
| 2011 FY | 245 Million USD | 122.73% |
| 2010 FY | 110 Million USD | 210.0% |
| 2009 FY | -100 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| MPH Health Care AG | 29.54 Million EUR | -7833.79% |
| Apontis Pharma AG | -11.3 Million EUR | 20837.942% |
| Dermapharm Holding SE | 62.36 Million EUR | -3658.338% |
| Evotec SE | -83.91 Million EUR | 2893.369% |
| MERCK Kommanditgesellschaft auf Aktien | 2.82 Billion EUR | 16.997% |
| PharmaSGP Holding SE | 16.39 Million EUR | -14195.298% |
| SynBiotic SE | -10.63 Million EUR | 22149.561% |